Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
GS-5894
- Development stage
- Unknown
- Lead developer
- Gilead Sciences
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
GS-5894 is an investigational small molecule non-nucleoside reverse transcriptase inhibitor (NNRTI) being developed by Gilead Sciences in collaboration with the Institute of Organic Chemistry and Biochemistry of the Czech Academy of Sciences (IOCB). It is designed for the treatment of HIV-1 infection with a pharmacokinetic and metabolic profile that supports once-weekly oral dosing. GS-5894 targets the HIV-1 reverse transcriptase enzyme and has demonstrated a high genetic barrier to resistance, maintaining potency against clinical isolates from NNRTI-experienced patients. It is currently in Phase I clinical development.
02
Targets
Human immunodeficiency virus type 1 reverse transcriptase
Beyond the preview
Go deeper on GS-5894.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on GS-5894.